GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Celgene Corporation (CELG) [hlAlert]

Rating:
Buy CELG
up 16.15 %

Celgene Corporation (CELG) rated Buy with price target $130 by Standpoint Research

Posted on: Thursday,  Jan 14, 2016  12:25 PM ET by Standpoint Research

Standpoint Research rated Buy Celgene Corporation (NASDAQ: CELG) on 01/14/2016, when the stock price was $105.93. Since
then, Celgene Corporation has gained 16.15% as of 01/14/2016's recent price of $123.04.
If you would have followed this Standpoint Research's recommendation on CELG, you would have gained 16.15% of your investment in 0 days.

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/14/2016 12:25 PM Buy
None
105.93 130.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy